IXC invex therapeutics ltd

I agree. Here's the catch 22 - had we partnered with a big...

  1. 427 Posts.
    lightbulb Created with Sketch. 60
    I agree. Here's the catch 22 - had we partnered with a big pharma, we would get the publicity but likely get screwed on the deal. This way, we don't get the publicity (until it really matters) and we negotiate favourable financial and commercial terms.

    I think the only way we'll now get the publicity we need is if we move into another indication. Tom said today that they have enough money to conduct a P3 trial (x1) and enough financial flexibility to look at another indications. That was a key point for me. It seems they are also aware of the need to branch out. This partnership can facilitate that. Peptron has
    developed a sustained-release version of Exenatide ((SR)-Exenatide) to investigate its neuroprotective effects in Parkinson's disease (https://clinicaltrials.gov/ct2/show/NCT04269642).
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
6.8¢
Change
0.000(0.00%)
Mkt cap ! $5.110M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 7402 6.8¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 31157 1
View Market Depth
Last trade - 10.04am 02/04/2025 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.